Elevated SAEs also found by other investigators: A study from French investigators (Nicolini et al., 2013 ASH meeting abstract #4020) found that in a cohort of 19 CML patients on Iclusig, 42% experienced CV events after a median of 8.5 months on drug, strikingly worse than a historical cohort of nilotinib-treated patients. Source: Oppenheimer/Ferreiro, December 6, 2013
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.